SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

$PEAR
Computer Software: Prepackaged Software
Technology
Get the next $PEAR alert in real time by email
SC 13G/A 1 d303025dsc13ga.htm SC 13G/A SC 13G/A

 

 

Securities and Exchange Commission

Washington, D.C. 20549

 

 

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

 

Pear Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

704723105

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 704723105    Schedule 13G    Page 1 of 9

 

  1    

  Names of Reporting Persons

 

  SB Global Advisers Limited

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  England and Wales

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

   5    

  Sole Voting Power

 

  0

   6  

  Shared Voting Power

 

  12,100,078

   7  

  Sole Dispositive Power

 

  0

   8  

  Shared Dispositive Power

 

  12,100,078

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  12,100,078

10  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  Not Applicable

11  

  Percent of Class Represented by Amount in Row 9

 

  8.8%

12  

  Type of Reporting Person

 

  CO


CUSIP No. 704723105    Schedule 13G    Page 2 of 9

 

  1    

  Names of Reporting Persons

 

  SoftBank Vision Fund II-2 L.P.

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Jersey

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

   5    

  Sole Voting Power

 

  0

   6  

  Shared Voting Power

 

  12,100,078

   7  

  Sole Dispositive Power

 

  0

   8  

  Shared Dispositive Power

 

  12,100,078

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  12,100,078

10  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  Not Applicable

11  

  Percent of Class Represented by Amount in Row 9

 

  8.8%

12  

  Type of Reporting Person

 

  PN


CUSIP No. 704723105    Schedule 13G    Page 3 of 9

 

  1    

  Names of Reporting Persons

 

  SVF II AIV (DE) LLC

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

   5    

  Sole Voting Power

 

  0

   6  

  Shared Voting Power

 

  12,100,078

   7  

  Sole Dispositive Power

 

  0

   8  

  Shared Dispositive Power

 

  12,100,078

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  12,100,078

10  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  Not Applicable

11  

  Percent of Class Represented by Amount in Row 9

 

  8.8%

12  

  Type of Reporting Person

 

  OO (Limited Liability Company)


CUSIP No. 704723105    Schedule 13G    Page 4 of 9

 

  1    

  Names of Reporting Persons

 

  SVF II Cobbler (DE) LLC

  2  

  Check the Appropriate Box if a Member of a Group

  (a)  ☐        (b)  ☐

 

  3  

  SEC Use Only

 

  4  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

   5    

  Sole Voting Power

 

  0

   6  

  Shared Voting Power

 

  12,100,078

   7  

  Sole Dispositive Power

 

  0

   8  

  Shared Dispositive Power

 

  12,100,078

  9    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  12,100,078

10  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  Not Applicable

11  

  Percent of Class Represented by Amount in Row 9

 

  8.8%

12  

  Type of Reporting Person

 

  OO (Limited Liability Company)


CUSIP No. 704723105    Schedule 13G    Page 5 of 9

 

ITEM 1.

(a)     Name of Issuer:

Pear Therapeutics, Inc. (the “Issuer”).

 

  (b)

Address of Issuer’s Principal Executive Offices:

200 State Street, 13th Floor, Boston, MA 02109.

 

ITEM 2.

(a)     Name of Person Filing:

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

SB Global Advisers Limited

SoftBank Vision Fund II-2 L.P.

SVF II AIV (DE) LLC

SVF II Cobbler (DE) LLC

 

  (b)

Address or Principal Business Office:

The principal business address for SB Global Advisers Limited is 69 Grosvenor Street, London W1K 3JP, United Kingdom. The principal business address for SoftBank Vision Fund II-2 L.P. is Crestbridge Limited, 47 Esplanade, St. Helier, Jersey, JE1 0BD. The principal business address for each of SVF II AIV (DE) LLC and SVF II Cobbler (DE) LLC is 251 Little Falls Drive, Wilmington, DE 19808.

 

  (c)

Citizenship of each Reporting Person is:

SB Global Advisers Limited is organized under the laws of England and Wales. SoftBank Vision Fund II-2 L.P. is organized under the laws of Jersey. Each of SVF II AIV (DE) LLC and SVF II Cobbler (DE) LLC is organized under the laws of the State of Delaware.

 

  (d)

Title of Class of Securities:

Class A common stock, par value $0.0001 per share (“Class A Common Stock”).

 

  (e)

CUSIP Number:

704723105

 

ITEM 3.

Not applicable.


CUSIP No. 704723105    Schedule 13G    Page 6 of 9

 

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of shares of Class A Common Stock of the Issuer based upon 137,799,218 shares of Class A Common Stock outstanding as of December 3, 2021, as reported in the Issuer’s prospectus filed with the SEC on January 3, 2022.

 

Reporting Person   

Amount

beneficially

owned

    

Percent

of class:

    Sole
power
to vote
or to
direct
the
vote:
     Shared
power to
vote or to
direct the
vote:
    

Sole
power to
dispose or
to direct
the
disposition

of:

    

Shared

power to

dispose or

to direct

the

disposition

of:

 

SB Global Advisers Limited

     12,100,078        8.8     0        12,100,078        0        12,100,078  

SoftBank Vision Fund II-2 L.P.

     12,100,078        8.8     0        12,100,078        0        12,100,078  

SVF II AIV (DE) LLC

     12,100,078        8.8     0        12,100,078        0        12,100,078  

SVF II Cobbler (DE) LLC

     12,100,078        8.8     0        12,100,078        0        12,100,078  

SVF II Cobbler (DE) LLC is the record holder of 12,100,078 shares of Class A Common Stock. SoftBank Vision Fund II-2 L.P. is the managing member of SVF II AIV (DE) LLC, which is the sole member of SVF II Cobbler (DE) LLC.

SB Global Advisers Limited has been appointed as manager and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund II-2 L.P.’s investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

 

ITEM 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

ITEM 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

 

ITEM 7.

Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

 

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.


CUSIP No. 704723105    Schedule 13G    Page 7 of 9

 

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

 

ITEM 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP No. 704723105    Schedule 13G    Page 8 of 9

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2022

 

SB Global Advisers Limited
By:  

/s/ Spencer Collins

Name:   Spencer Collins
Title:   Director
SoftBank Vision Fund II-2 L.P.
By: SB Global Advisers Limited, its Manager
By:  

/s/ Spencer Collins

Name:   Spencer Collins
Title:   Director
SVF II AIV (DE) LLC
By:  

/s/ Ian McLean

Name:   Ian McLean
Title:   Director
SVF II Cobbler (DE) LLC
By:  

/s/ Ian McLean

Name:   Ian McLean
Title:   Director


CUSIP No. 704723105    Schedule 13G    Page 9 of 9

 

LIST OF EXHIBITS

 

Exhibit No.

  

Description

99    Joint Filing Agreement.
Get the next $PEAR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PEAR

DatePrice TargetRatingAnalyst
1/26/2022$5.00Neutral
B of A Securities
1/20/2022$11.00Outperform
Credit Suisse
1/3/2022$12.00Buy
BTIG Research
12/29/2021$13.00Buy
Citigroup
12/22/2021$16.00Buy
Chardan Capital
12/16/2021Outperform
Cowen & Co.
More analyst ratings

$PEAR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

    Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
  • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

    SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Software: Prepackaged Software

$PEAR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PEAR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PEAR
SEC Filings

See more

$PEAR
Leadership Updates

Live Leadership Updates

See more
  • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology
  • Jorge Gomez Joins Moderna as Chief Financial Officer

    CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

    $CAH
    $MRNA
    $PEAR
    $XRAY
    Other Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Prepackaged Software

$PEAR
Financials

Live finance-specific insights

See more
  • Pear Therapeutics Reports Third Quarter 2022 Results

    Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

    Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

    $PEAR
    Computer Software: Prepackaged Software
    Technology
  • Pear Therapeutics Reports Second Quarter 2022 Results

    20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

    $PEAR
    Computer Software: Prepackaged Software
    Technology

$PEAR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more